as described by the Institute of Medicine (now renamed the National Academy of Medicine).
Best practices for meaningful and effective patient and stakeholder engagement in research will continue to evolve; however, four engagement principles have been proposed by PCORI 8 . The first principle states that roles and decision-making should reflect reciprocal relationships so that all who participate in research benefit from the research process. The second principle describes partnerships as being committed to diversity, cultural competence and fair compensation. The third principle involves co-learning, sometimes referred to as bidirectional learning, whereby everyone's skills and experiences benefit the partnership. The fourth principle underscores the importance of transparency, honesty and trust in decision-making and sharing of information. Even if there is conceptual agreement with these four principles, patients, researchers and the public are still learning how to implement the principles in practice, especially when there are time and budgetary constraints. Moreover, there is general agreement that many projects engage only a subset of the broader population affected by a disease and that greater diversity is a desirable goal. Patients who are routinely engaged might not be representative of the community as a whole. The field of rheumatology needs to explore how to engage a diversity of participants to ensure that 'every voice is heard. ' Time and budgetary constraints apply to all members of the partnership. Patients and members of the public, just like researchers and other stakeholders, have competing demands on their time and are motivated to continue engagement in research only when they feel that their voices are heard, that their opinions matter and that they are respected and valued members of the partnership. In some cases, patients and members of the public bring unique skillsets from their personal or professional lives that benefit both scientific aspects of the partnership as well as the patient-centeredness of the research. In paediatric research, this possibility extends to the parents of the patients. Many individuals have 'day jobs' that could help with technical aspects of conducting research. For example, an information technology specialist whose child has JIA might have critical insights regarding electronic data capture. Another parent might have artistic or graphic illustration skills that could assist with developing recruitment brochures or lay summaries of the study findings. Patients should no longer merely be the focus of research; patients should guide what to study and how to study it, as well as how to engage patients when doing research and how to communicate findings.
As the science of engagement continues to evolve, there will be unique opportunities for a more holistic approach to partnering in research across the diversity of patients and the continuum of research 9 . Such opportunities should be embraced by patients and researchers alike to improve the relevance of clinical research and health outcomes. Patients are the true north, pointing researchers and funders in the right direction to conduct patient-centered research in support of shared decision-making and improved health. 
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N e w s & V i e w s
Vitamin D has a pivotal role in skeletal health and in the maintenance of normal calcium homeostasis 1 . Therefore, it is not surprising that vitamin D supplements are widely used to prevent rickets in children and to improve bone strength and reduce the risk of fracture in elderly individuals. [8] [9] [10] together weighted more than half of the whole meta-analysis.
Several other confounders might have influenced the results of the meta-analysis 2 . First, the majority of patients in the included trials were community-dwelling individuals (85%) who were not selected for underlying illness, and a lack of information was shown about the presence of comorbidities that might influence the risk of falls and fractures, irrespective of vitamin D status. Second, only 25% of the included trials used calcium supplementation 2 . This factor might have confounded the results (in particular for studies performed in countries where a reduced dietary calcium intake is common), as calcium deficiency can neutralize the possible positive effects of vitamin D on BMD and fractures 3 . Third, as noted by Bolland et al. 2 , small studies of short duration should be interpreted with caution; indeed, 52% of the selected RCTs included <200 patients and 68% had an overall length of <1 year. This consideration renders any clear-cut conclusion as to the effect of vitamin D supplementation on the risk of fracture questionable. Finally, a consistent proportion of the RCTs included patients with normal or nearly normal serum concentrations of 25(OH)D.
Overall, although the results of the metaanalysis by Bolland et al. 2 are of clinical relevance and do not support the widespread use of vitamin D supplementation for musculoskeletal health in community-dwelling individuals, they do not lessen the importance of vitamin D supplementation in individuals with low serum concentrations of vitamin D (particularly in those at high risk of bone loss, falls and fractures), or its additive use in patients with osteoporosis being treated with anti-resorptive or osteoanabolic agents. The results of the meta-analysis by Bolland et al. 2 did not show vitamin D to have a positive effect in the prevention of fractures or falls, or to have a clinically meaningful effect on maintaining BMD. These findings prompted the authors to conclude that there is little justification for the use of vitamin D supplements to maintain or improve musculoskeletal health, and no justification for further trials into vitamin D supplements for musculoskeletal outcomes 2 . However, these conclusions should be interpreted with caution owing to the heterogeneity of the studies included in the meta-analysis and the failure of many of the RCTs to exclude the possible effects of vitamin D supplementation on the outcomes selected in the meta-analysis. In fact, most of the RCTs included in the meta-analysis were underpowered to answer the question of fracture prevention and were not specifically designed to assess the role of vitamin D supplementation in the prevention of falls and fractures as a primary end point. Up to 50% of these studies did not consider both falls and fractures, and information about these outcomes was only included in the safety information. Overall, the slight improvement in BMD that occurred with vitamin D supplementation in pooled analy sis was not considered by the authors to be a clinically meaningful These characteristics were not completely achieved in the majority of studies included by Bolland et al. in their meta-analysis 2 (for example, only 11% and 6% of RCTs rated for fracture outcome met, respectively, four or five of the recommendations provided in Box 1). Indeed, in 32% of the selected RCTs, patients were taking <1,000 IU per day of vitamin D, although daily doses of 800-1,000 IU are required to maintain serum 25(OH)D concentrations ≥75 nmol/l (considered to be a safe cut-off point for skeletal health as >30% of patients with a serum 25(OH)D concentration of 50-75 nmol/l have histomorphometric features of osteomalacia 6 ). Notably, adequate concentrations of vitamin D were not reached in all patients in 42% of the RCTs considered by Bolland and colleagues 2 , including in some large RCTs 7, 8 , which affects the results of the meta-analysis. For example, in the large Vitamin D Assessment (ViDA) RCT (which was not designed to assess the effect of vitamin D on the risk of fractures), adequate serum 25(OH)D concentrations (>75 nmol/l) were obtained in only 33% of the individuals involved 8 . Likewise, in two other RCTs 9,10 , intermittent supplementation regimens of ergocalciferol were used (100,000 IU orally once every 4 months or 300,000 IU intramuscularly once every year). These regimens are no longer recommended as they are associated with oscillations in serum 25(OH)D concentrations (meaning that serum concentrations are not maintained above the normal threshold during the entire treatment period)
Box 1 | Proposed recommendations for vitamin D trials on musculoskeletal outcomes
The usefulness of data from trials of vitamin D supplementation for musculoskeletal outcomes could be improved by adhering to the following proposed recommendations:
• the inclusion of patients from high-risk populations (such as patients who have become institutionalized or individuals with a bone mineral density (BmD) within the osteopenic range); • the inclusion of patients with a baseline 25-hydroxyvitamin D (25(oH)D) concentration of <75 nmol/l; • the use of cholecalciferol doses equivalent to ≥1,000 Iu per day (either daily or monthly regimens a ); • the use of calcium supplements for individuals with a calcium intake ≤1,000 mg per day;
• a target 25(oH)D concentration of ≥75 nmol/l for the duration of the study;
• a study duration of ≥2 years for the evaluation of BmD and fractures;
• the registration of all major comorbidities. a Depending on the baseline 25(oH)D concentration, consider using a cumulative high dose to rapidly achieve a healthy vitamin D status (≥75 nmol/l) during the entry phase of the study.
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